Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Ironwood Pharmaceuticals, Inc. IRWD
$10.13
-$0.13 (-1.32%)
На 18:00, 12 мая 2023
+57.95%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
1607054370.00000000
-
week52high
12.66
-
week52low
9.73
-
Revenue
410596000
-
P/E TTM
9
-
Beta
0.92456700
-
EPS
0.95000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 12:30
Описание компании
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Wells Fargo | Equal-Weight | Equal-Weight | 16 авг 2022 г. |
| Piper Sandler | Overweight | 22 апр 2022 г. | |
| Morgan Stanley | Equal-Weight | Equal-Weight | 12 окт 2021 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 16 июл 2021 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 22 февр 2021 г. |
| Piper Sandler | Overweight | 29 авг 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| MCCOURT Thomas A | A | 742585 | 30145 | 17 янв 2023 г. |
| Rickard Jason | A | 366823 | 18087 | 17 янв 2023 г. |
| Shetzline Michael | A | 280908 | 14663 | 17 янв 2023 г. |
| MCCOURT Thomas A | D | 0 | 110962 | 05 янв 2023 г. |
| MCCOURT Thomas A | D | 712440 | 110962 | 05 янв 2023 г. |
| MCCOURT Thomas A | A | 823402 | 110962 | 05 янв 2023 г. |
| DENNER ALEXANDER J | A | 91985 | 1244 | 15 дек 2022 г. |
| Rickard Jason | D | 348736 | 27000 | 14 дек 2022 г. |
| Davis Andrew | D | 154213 | 3335 | 21 ноя 2022 г. |
| Emany Sravan Kumar | D | 78422 | 6578 | 21 ноя 2022 г. |
Новостная лента
Ironwood Pharmaceuticals, Inc. (IRWD) Q1 2023 Earnings Call Transcript
Seeking Alpha
06 мая 2023 г. в 18:23
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD ) Q1 2023 Results Conference Call May 4, 2023 8:30 AM ET Company Participants Matt Roache - Director of Investor Relations Tom McCourt - CEO Mike Shetzline - Chief Medical Officer Sravan Emany - Chief Financial Officer Conference Call Participants Tim Chiang - Capital One Boris Peaker - Cowen Jacob Hughes - Wells Fargo Securities Operator Good day, and welcome to the Ironwood Pharmaceuticals Q1 2023 Investor Update Conference Call. Today's call is being recorded [Operator Instructions].
Ironwood Pharmaceuticals (IRWD) Surpasses Q1 Earnings and Revenue Estimates
Zacks Investment Research
04 мая 2023 г. в 10:41
Ironwood Pharmaceuticals (IRWD) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.21 per share a year ago.
Ironwood to Present New Data at Digestive Disease Week® 2023 Demonstrating Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old
Business Wire
24 апр 2023 г. в 07:30
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, announced today that the company will present findings during the 2023 Digestive Disease Week® (DDW) from studies on the potential of linaclotide for children and adolescents ages 6-17 years-old with functional constipation. DDW is being held from May 6 through May 9 in Chicago, IL. Functional constipation in children is defined as a condition with hard, infrequent bowel movements that are o.
Ironwood Pharmaceuticals to Participate in Upcoming Investor Conferences
Business Wire
27 февр 2023 г. в 16:01
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that management will participate in the following investor conferences: Cowen 43rd Annual Health Care Conference on Monday, March 6, 2023 at 9:10 a.m. ET at the Boston Marriott Copley Place Barclays Global Healthcare Conference on Tuesday, March 14, 2023 at 8:00 a.m.
Ironwood (IRWD) Q4 Earnings Miss, Linzess Volume Increases
Zacks Investment Research
17 февр 2023 г. в 12:48
Though Ironwood (IRWD) missed both Q4 earnings and sales estimates, the total prescription demand for the sole-marketed drug Linzess rose 9% year over year.